SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MorphoSys AG (MOR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ghmm who wrote (414)8/6/2013 5:52:57 AM
From: Germanecki  Read Replies (1) of 421
 
Hi ghmm,
after the two deals with GSK and Celegene, the propietery pipeline is shrinked.
Particulary if you look to the inflammatory section.
Moroney named it a gaap in the preclinical area. And Morphosys has to close it.
There is some stuff in the very early area, but they are looking actively for inlicensing of targets, projects, small companies or technologies.
We have to wait.....
Next expected news are propably:
Celgene deal clearance by authorities and new prognose für 2013.
New studies for MOR103 and MOR202.
Data for MOR208 P1.
LFG316, BYM338 or BPS804: Next Phase 3 to start within next year.
Ylanthia deal.

I think there are a lot of news coming to confirm the better ratings of Morphosys.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News